Please assess the completion status of the following clinical trial:

Trial Title: Secondary Prevention of Atrial Fibrillation (Impact of Renin-Angiotensin-Aldosterone System Inhibition)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be in atrial fibrillation confirmed by 12 lead EKG.~* blood pressure \> 90 mmHg~* Patient without cardiopulmonary symptoms~* 18+ years of age~Exclusion Criteria:~* Contraindiction to warfarin~* Recent (within 6 months) MI or cardiac revascularization~* Recent (within 6 months) CVA or TIA~* NYHA Class IV CHF~* Active thyroid disease~* Major hepatic dysfunction~* Renal dysfunction (\>2 mg/dL)~* Hyperkalemia (\>4.6 mEq/L)~* Hyponatremia (\<130 mEq/L)~* Currently taking a Vaughn-Williams Type I or III antiarrhythmic drug~* History of ARB intolerance~* Contraindication to ARB therapy~* Pregnancy~* Female of childbearing age~* Age \< 18 years of age~* Inability to give informed consent~* Other medical conditions calling 1 year survival into question

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A Group 1 no drug (Type: EXPERIMENTAL): Patients who have not taken ACE/ARB, randomized to no drug.
- A Group 2 (Type: EXPERIMENTAL): Patients who have not taken ACE/ARB, randomized to take cozaar.
- B (Type: EXPERIMENTAL): Patients currently taking ACE/ARB will have their prescription changed to cozaar.

Based on this trial design, predict the completion outcome and termination type (if applicable).